Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer

Showing 15 posts of 894 posts found.

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

May 22, 2025
Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …

News
Press release
Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

August 13, 2024
Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …

News

New Real-World Data Published in Journal of Cardiac Failure on Effectiveness

August 6, 2024
Research and Development Cardiac, Cardiology, Pfizer

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …

News
Press release

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024
Research and Development DMD, Musculo-skeletal disorder, Pfizer, duchenne muscular dystropy, gene therapy

Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin …

News

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024
Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis

NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).

News
anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024
Medical Communications FDA, Haematology, Pfizer, haemophilia

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …

News

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024
Medical Communications Emblaveo, European Commission, Immunology, Pfizer

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) for the treatment of adult …

News

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

February 20, 2024
Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …

News

EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

December 12, 2023
Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma

Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …

News

CDC Advisory Committee recommends Pfizer’s RSV vaccine

September 25, 2023
Medical Communications Abrysvo, Immunology, Pfizer, RSV

Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has …

News

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

September 7, 2023
Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …

News

FDA approves Pfizer’s vaccine for the prevention of RSV in children

August 22, 2023
Research and Development FDA, Paediatrics, Pfizer, RSV

On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo for the prevention of respiratory …

News

FDA grants accelerated approval to Pfizer’s Elrexfio

August 15, 2023
Medical Communications Elrexfio, FDA, Oncology, Pfizer, accelerated approval

Pfizer has that the US Food and Drug Administration (FDA) has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment …

News
genes

AstraZeneca’s Alexion partners with Pfizer for rare disease therapies

July 28, 2023
Research and Development Alexion, AstraZeneca, Pfizer, Rare Diseases, genomics, rare disease

Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and licence agreement with Pfizer. The …

News
Vaccine image

Pfizer shares new data from phase 2 trial for GBS maternal vaccine candidate

July 20, 2023
Research and Development Immunology, Pfizer, Vaccine, clinical trial

Pfizer has announced new data from its phase 2 study which assessed its hexavalent capsular polysaccharide (CPS) conjugate Group B …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026